MA46470A - 1h-imidazo[4,5-b]pyridin-2(3h)-ones substituées et leur utilisation en tant que modulateurs du récepteur glun2b - Google Patents
1h-imidazo[4,5-b]pyridin-2(3h)-ones substituées et leur utilisation en tant que modulateurs du récepteur glun2bInfo
- Publication number
- MA46470A MA46470A MA046470A MA46470A MA46470A MA 46470 A MA46470 A MA 46470A MA 046470 A MA046470 A MA 046470A MA 46470 A MA46470 A MA 46470A MA 46470 A MA46470 A MA 46470A
- Authority
- MA
- Morocco
- Prior art keywords
- glun2b
- imidazo
- pyridin
- modulators
- receiver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404798P | 2016-10-06 | 2016-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46470A true MA46470A (fr) | 2019-08-14 |
Family
ID=61831306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046470A MA46470A (fr) | 2016-10-06 | 2017-10-05 | 1h-imidazo[4,5-b]pyridin-2(3h)-ones substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10617676B2 (enExample) |
| EP (1) | EP3523311B1 (enExample) |
| JP (1) | JP7001682B2 (enExample) |
| KR (1) | KR20190056435A (enExample) |
| CN (2) | CN110062761B (enExample) |
| AR (1) | AR109810A1 (enExample) |
| AU (1) | AU2017340602A1 (enExample) |
| BR (1) | BR112019006691A2 (enExample) |
| CA (1) | CA3038820A1 (enExample) |
| CL (1) | CL2019000882A1 (enExample) |
| EA (1) | EA201990848A1 (enExample) |
| ES (1) | ES2950881T3 (enExample) |
| IL (1) | IL265757A (enExample) |
| MA (1) | MA46470A (enExample) |
| MX (1) | MX2019003980A (enExample) |
| PH (1) | PH12019500676A1 (enExample) |
| TW (1) | TW201819376A (enExample) |
| WO (1) | WO2018067786A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3180329B1 (en) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| PT3180315T (pt) | 2014-08-15 | 2020-05-27 | Janssen Pharmaceuticals Inc | Pirazoles |
| MX2018000352A (es) | 2015-07-09 | 2018-08-15 | Janssen Pharmaceutica Nv | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| CA3281817A1 (en) | 2016-11-28 | 2026-03-02 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11492345B2 (en) * | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| IL309843B2 (en) | 2018-05-30 | 2026-05-01 | Praxis Prec Medicines Inc | History of [4,2,1]triazolo[3,4-a]pyridines and their use as sodium ion channel modulators |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| CN109499614B (zh) * | 2018-12-12 | 2021-06-04 | 怀化学院 | MOPs负载双齿螯合型金属催化剂及其制备方法 |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| EP3983413A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
| US20220324860A1 (en) * | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| SG11202112407PA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| AU2020291188A1 (en) * | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| PE20221280A1 (es) | 2019-11-27 | 2022-09-05 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos |
| AU2021233745B2 (en) * | 2020-03-11 | 2024-05-02 | Anygen Co., Ltd. | Composition for anti-diabetes and anti-obesity comprising novel compound |
| BR112022023559A2 (pt) * | 2020-05-21 | 2023-01-24 | Stemsynergy Therapeutics Inc | Inibidores de notch e seus usos |
| CN112939986B (zh) * | 2021-02-18 | 2023-06-13 | 新乡医学院 | 一种吡唑并嘧啶类化合物的合成方法 |
| KR20230037391A (ko) * | 2021-09-09 | 2023-03-16 | 애니젠 주식회사 | 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| KR20250005348A (ko) | 2022-04-26 | 2025-01-09 | 프락시스 프리시젼 메디신즈, 인크. | 신경 장애의 치료 |
| WO2025224308A1 (en) * | 2024-04-25 | 2025-10-30 | Scenic Immunology B.V. | Qpctl inhibitors |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| CA2262502C (en) | 1996-07-31 | 2002-11-26 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same |
| WO2002000629A1 (en) * | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| KR20040111445A (ko) | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌 |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| CN1656079A (zh) * | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| AU2005214375A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| EP1805142A4 (en) | 2004-09-23 | 2009-06-10 | Reddy Us Therapeutics Inc | PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR20100017372A (ko) | 2007-05-25 | 2010-02-16 | 애보트 게엠베하 운트 콤파니 카게 | 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물 |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| WO2009028543A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 置換ピラゾール誘導体 |
| WO2009058261A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | Modulation of sleep with nr2b receptor antagonists |
| US20110053951A1 (en) | 2008-03-27 | 2011-03-03 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| EP2298731A4 (en) | 2008-06-25 | 2011-09-21 | Takeda Pharmaceutical | AMIDE COMPOUND |
| DK2308877T3 (da) * | 2008-08-05 | 2014-04-22 | Daiichi Sankyo Co Ltd | Imidazopyridin-2-on-derivater |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| CN102264743B (zh) * | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| EP2579717A4 (en) * | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| JP2012188363A (ja) * | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| CN105073747B (zh) | 2013-03-15 | 2017-06-06 | 普莱希科公司 | 杂环化合物及其应用 |
| KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| JP6612751B2 (ja) | 2013-07-31 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
| AU2015296893A1 (en) | 2014-07-28 | 2017-02-02 | Safemate Australia Pty Ltd | Systems and methods for making personal emergency information available to third parties |
| EP3180329B1 (en) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| PT3180315T (pt) | 2014-08-15 | 2020-05-27 | Janssen Pharmaceuticals Inc | Pirazoles |
| WO2016081649A1 (en) * | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| MX2018000352A (es) | 2015-07-09 | 2018-08-15 | Janssen Pharmaceutica Nv | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| CN110831593A (zh) | 2017-06-14 | 2020-02-21 | 特维娜有限公司 | 用于调节s1p1活性的化合物及其使用方法 |
| EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
| US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| EP3983413A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
| AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| SG11202112407PA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
-
2017
- 2017-10-03 TW TW106134127A patent/TW201819376A/zh unknown
- 2017-10-05 US US15/725,500 patent/US10617676B2/en active Active
- 2017-10-05 CN CN201780075930.5A patent/CN110062761B/zh active Active
- 2017-10-05 MA MA046470A patent/MA46470A/fr unknown
- 2017-10-05 JP JP2019518219A patent/JP7001682B2/ja active Active
- 2017-10-05 WO PCT/US2017/055278 patent/WO2018067786A1/en not_active Ceased
- 2017-10-05 EA EA201990848A patent/EA201990848A1/ru unknown
- 2017-10-05 AR ARP170102779A patent/AR109810A1/es unknown
- 2017-10-05 AU AU2017340602A patent/AU2017340602A1/en not_active Abandoned
- 2017-10-05 KR KR1020197012678A patent/KR20190056435A/ko not_active Withdrawn
- 2017-10-05 MX MX2019003980A patent/MX2019003980A/es unknown
- 2017-10-05 EP EP17859165.7A patent/EP3523311B1/en active Active
- 2017-10-05 CN CN202210460371.2A patent/CN114989164B/zh active Active
- 2017-10-05 ES ES17859165T patent/ES2950881T3/es active Active
- 2017-10-05 BR BR112019006691A patent/BR112019006691A2/pt not_active Application Discontinuation
- 2017-10-05 CA CA3038820A patent/CA3038820A1/en active Pending
-
2019
- 2019-03-28 PH PH12019500676A patent/PH12019500676A1/en unknown
- 2019-04-01 IL IL265757A patent/IL265757A/en unknown
- 2019-04-02 CL CL2019000882A patent/CL2019000882A1/es unknown
-
2020
- 2020-03-03 US US16/807,385 patent/US11207298B2/en not_active Expired - Fee Related
-
2021
- 2021-09-14 US US17/474,631 patent/US11759455B2/en active Active
-
2023
- 2023-06-29 US US18/344,169 patent/US20230338341A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20230338341A1 (en) | 2023-10-26 |
| CN114989164B (zh) | 2024-08-13 |
| CN110062761B (zh) | 2022-05-13 |
| CN114989164A (zh) | 2022-09-02 |
| JP7001682B2 (ja) | 2022-01-19 |
| EA201990848A1 (ru) | 2019-08-30 |
| US11207298B2 (en) | 2021-12-28 |
| KR20190056435A (ko) | 2019-05-24 |
| IL265757A (en) | 2019-06-30 |
| US20180125826A1 (en) | 2018-05-10 |
| AR109810A1 (es) | 2019-01-23 |
| PH12019500676A1 (en) | 2019-12-02 |
| BR112019006691A2 (pt) | 2019-06-25 |
| US11759455B2 (en) | 2023-09-19 |
| MX2019003980A (es) | 2019-06-10 |
| EP3523311B1 (en) | 2023-06-07 |
| EP3523311C0 (en) | 2023-06-07 |
| CN110062761A (zh) | 2019-07-26 |
| US20230000833A1 (en) | 2023-01-05 |
| TW201819376A (zh) | 2018-06-01 |
| CA3038820A1 (en) | 2018-04-12 |
| EP3523311A1 (en) | 2019-08-14 |
| EP3523311A4 (en) | 2020-03-18 |
| US10617676B2 (en) | 2020-04-14 |
| CL2019000882A1 (es) | 2019-06-21 |
| ES2950881T3 (es) | 2023-10-16 |
| WO2018067786A1 (en) | 2018-04-12 |
| AU2017340602A1 (en) | 2019-04-18 |
| US20210069155A1 (en) | 2021-03-11 |
| JP2019530695A (ja) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3523311A4 (en) | SUBSTITUTED 1H-IMIDAZO [4,5-B] PYRIDINE-2 (3H) -ONE AND THE USE THEREOF AS GLUN2B RECEPTOR MODULATORS | |
| FR22C1058I2 (fr) | Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide | |
| CL2017003486A1 (es) | Lactamas bicíclicas y métodos de uso de las mismas | |
| MA46228A (fr) | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll | |
| EP3416948C0 (en) | SULFONYLUREAS CONTAINING AN INDACENE GROUP AS AN ANTI-INFLAMMATORY AGENT | |
| ES2796903T8 (es) | Procedimiento de uso de inmunoconjugados anti-CD79b | |
| ZA201705802B (en) | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives | |
| DK3674302T3 (da) | 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner | |
| EP3160940A4 (en) | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds | |
| ME03672B (me) | 1h-pirazolo[4,3-b]piridini kao pde1 inhibitori | |
| MA39838B1 (fr) | Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 | |
| EP3452481A4 (en) | IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS | |
| IL252311A0 (en) | 4-oxo-4,3-dihydro-3,2,1-benzotriazines as G protein-coupled receptor modulators 139 | |
| DK3348557T3 (da) | Imidazo[1,2-a]pyridiner til behandling eller forebyggelse af hyperurekæmi eller gigt | |
| EP3328840A4 (en) | SUBSTITUTED BICYCLIC TRIAZOL COMPOUNDS AS PDE2 INHIBITORS | |
| MA43840A (fr) | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées | |
| SI3114126T1 (sl) | Derivati 1,2-dihidro-3H-pirolo(1,2-C)imidazol-3-ona in njihova uporaba kot antibakterijska sredstva | |
| HUE053428T2 (hu) | Eljárás otikus progenitorok elõállítására | |
| DK3535263T3 (da) | Substituerede pyrido[3,4-b]indoler til behandling af bruskforstyrrelser | |
| EP3487851A4 (en) | AMINOPYRIDE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | |
| FR3021414B1 (fr) | Miroir colore | |
| HRP20180788T1 (hr) | [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti | |
| LT3230289T (lt) | 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai | |
| EP3415129A4 (en) | TOTALLY SUCTIONFUL ARTICLE | |
| EP3371192A4 (en) | PODOPHYL LOTOXIN DERIVATIVES AND THEIR USE |